D. A. Van Echo
University of Maryland, Baltimore
29 Papers
304 Citations
D. A. Van Echo is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Carboplatin & Chemotherapy. The author has an hindex of 14, co-authored 29 publications.
Chat about Author
Papers
•Journal Article
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.
TL;DR: In this article, the authors developed equations to calculate carboplatin dosage for any patient based on that patient9s creatinine clearance, body surface area, pretreatment platelet count, desired platelet nadir, and status of prior chemotherapy.
208
•Journal Article
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Barbara A. Conley,Merrill J. Egorin,Nancy Tait,D M Rosen,Edward A. Sausville,G Dover,R J Fram,D. A. Van Echo +7 more
TL;DR: Because peak plasma concentrations near those effective in vitro (0.5-1 mM) were achieved, but butyrate disappeared from plasma by 5 h after dose, this work is pursuing dose escalation with dosing three times daily, beginning at a dose of 450 mg/kg/day.
158
Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.
TL;DR: Preliminary data suggest that carboplatin has activity against advanced squamous-cell carcinoma of the head and neck comparable with the results reported with cisplatin alone in similar patient populations.
118
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study
Mark J. Ratain,Gary L. Rosner,S L Allen,Mary E. Costanza,D. A. Van Echo,I. C. Henderson,Richard L. Schilsky +6 more
TL;DR: The highly variable toxicity of amonafide is primarily due to genetic differences in N-acetylation, and other genetic (race) and acquired factors also appear to influence the extent of toxicity observed following administration of this agent.
51
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.
Chandra P. Belani,Merrill J. Egorin,Jeffrey Abrams,D. Hiponia,Mario A. Eisenberger,Joseph Aisner,D. A. Van Echo +6 more
TL;DR: The concept of individualized dosing of carboplatin and the underlying pharmacokinetic/pharmacodynamic relationships are supported and represents an interesting pharmacodynamic and quantitative approach to studying potential drug-drug interactions and defining appropriate dosages for combination chemotherapy.
43